In the last decade, the approval of immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1, has improved survival and long-term responses in patients with non-small cell lung cancer (NSCLC) without anaplastic lymphoma kinase (ALK) or epidermal growth factor receptor (EGFR) driver mutations [3,4,5,6]. This evidence concerns the gene ALK and non-small cell lung carcinoma.